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Abstract. Telapristone is a selective progesterone antagonist that is being developed for the long-term
treatment of symptoms associated with endometriosis and uterine ﬁbroids. The population pharmaco-
kinetics of telapristone (CDB-4124) and CDB-4453 was investigated using nonlinear mixed-effects
modeling. Data from two clinical studies (n=32) were included in the analysis. A two-compartment
(parent) one compartment (metabolite) mixture model (with two populations for apparent clearance)
with ﬁrst-order absorption and elimination adequately described the pharmacokinetics of telapristone
and CDB-4453. Telapristone was rapidly absorbed with an absorption rate constant (Ka) of 1.26 h
−1.
Moderate renal impairment resulted in a 74% decrease in Ka. The population estimates for oral
clearance (CL/F) for the two populations were 11.6 and 3.34 L/h, respectively, with 25% of the subjects
being allocated to the high-clearance group. Apparent volume of distribution for the central
compartment (V2/F) was 37.4 L, apparent inter-compartmental clearance (Q/F) was 21.9 L/h, and
apparent peripheral volume of distribution for the parent (V4/F) was 120 L. The ratio of the fraction of
telapristone converted to CDB-4453 to the distribution volume of CDB-4453 (Fmetest) was 0.20/L.
Apparent volume of distribution of the metabolite compartment (V3/F) was ﬁxed to 1 L and apparent
clearance of the metabolite (CLM/F) was 2.43 L/h. A two-compartment parent-metabolite model
adequately described the pharmacokinetics of telapristone and CDB-4453. The clearance of telapristone
was separated into two populations and could be the result of metabolism via polymorphic CYP3A5.
KEY WORDS: CDB-4453; mixture model; parent-metabolite; population pharmacokinetics; telapristone
(CDB-4124).
INTRODUCTION
Over the last 25 years, several progesterone receptor
antagonists have been evaluated for the treatment of
progesterone-dependent diseases such as endometriosis and
uterine leiomyoma (1). However, many of the potential
candidates also exhibited potent antiglucocorticoid activity
(1,2). Additional anti-progestins have been synthesized and
tested in order to identify candidates that are progesterone
antagonist with little to no antiglucocorticoid activity. Telapri-
stone (US adopted name: telapristone acetate) was one of the
compounds developed by the Contraception and Reproduc-
tive Health Branch (National Institute of Child Health and
Human Development) for the chronic treatment of symptoms
associated with endometriosis and leiomyoma (3).
Telapristone opposes progesterone action at the molecular
and receptor level, and has been shown in animals to exhibit
potent anti-progesterone effects. Administration of telapristone
to endometriosis-induced cynomolgus monkeys demonstrated
that telapristone lead to reduction in the height and develop-
mentoftheendometriumaswellaschangesinthemitoticindex,
glands and stroma. It was also noted that telapristone was not
associated with any antiglucocorticoid activity, as shown by a
lack of measurable increase in serum cortisol. Clinical evalua-
tion of hormone levels and ovulation showed that telapristone
did not affect serum estrogen or progesterone and did not
appear to affect ovulation when used once every 7 days.
A phase I/II study (ZN001) in pre-menopausal women
(n=30) with symptomatic leiomyoma was completed (Trial
identiﬁcation number: CTNNCT01069094). It consisted of a
single-dose pharmacokinetic arm (telapristone only) followed
by a randomized, double-blind, placebo-controlled safety trial
of three doses of telapristone (12.5, 25, and 50 mg) given once
a day for 3 months and intramuscular (3.75 mg) Lupron
Depot (leuprolide acetate) given once a month for 3 months.
Single-dose pharmacokinetic results showed a bi-phasic
decline in concentration for all subjects. Telapristone was
rapidly absorbed reaching peak levels in 0.5–2 h. Telapristone
exhibited linear kinetics over the dose ranges tested. Overall
ﬁndings were more favorable to the telapristone treatment
groups, particularly the 50 mg when compared with Lupron
Depot and placebo. Telapristone subjects experienced fewer
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The reduced antiglucocorticoid activity (5), indications
that physiologic concentrations of estrogen are preserved and
results from efﬁcacy trials for both uterine ﬁbroids and
endometriosis (4,7–9), suggest that telapristone may offer
advantages in both safety and efﬁcacy that other currently
available treatments do not.
Data in mice indicates that telapristone is primarily
metabolized in the liver. It has been proposed that telapri-
stone (Fig. 1) undergoes demethylation to produce mono
(CDB-4453) and didemethylated metabolites as well as
hydroxylation of the propynyl group to produce the hydroxy-
lated metabolite. Like mifepristone, it is proposed that
metabolism of telapristone to the monodemethylated and
hydroxylated metabolite is rapid, but formation of the
didemethylated metabolite occurs more slowly and to a much
lesser extent (6,10,11). Out of the three characterized
metabolites, in vitro data indicated that CDB-4453 was
equipotent to CDB-4124 as an anti-progesterone. In addition,
a study evaluating the in vitro activity of CDB-4453 showed
that it had less antiglucocorticoid activity than telapristone
(5,6). Since CDB-4453 and telapristone share similar anti-
progestational activity in vitro, the presence of CDB-4453
might contribute signiﬁcantly to the in vivo anti-progesterone
activity of telapristone. Therefore, it is important to under-
stand the kinetics of both telapristone and CDB-4453.
Information pertaining to the pharmacokinetics and
sources of variability within parameter estimates for telapri-
stone and CDB-4453 is limited. The aim of this analysis was
to develop a pharmacokinetic model for telapristone and
CDB-4453, evaluate the effects of covariates on the inter-
individual variability associated with parameters, and simu-
late concentration time proﬁles of telapristone and CDB-4453
in order to assess the range of variability in pharmacokinetic
parameters.
MATERIALS AND METHODS
Description of Studies
Study ZP-005 was a phase I/II, open-label study to
evaluate the safety and pharmacokinetics of telapristone in
female patients with moderate hepatic impairment (meeting
the Child–Pugh class B severity criteria) versus healthy
volunteers. Patients and volunteers received a single oral
dose of 25 mg of telapristone acetate (fasted) followed by
50 mg of telapristone acetate (fasted) after a 14-day washout
period (Trial identiﬁcation number: NCT00741273).
Study ZP-006 was a phase I/II single-dose open-label
parallel study to evaluate the pharmacokinetics and safety
proﬁle of telapristone in female patients with mild and
moderate renal impairment versus healthy volunteers. Sub-
jects received a single oral dose of 50 mg of telapristone
acetate (fasted) (Trial identiﬁcation number: NCT00787618).
Pharmacokinetic samples for both studies were taken at
pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 5, 7, 9, 12, 16, 20, 24,
28, 32, 36, 40, 44, and 48 h postdose.
All protocols, amendments, and informed consent forms
were reviewed and approved by an Institutional Review
Board (IRB) at each study site. The study did not start until
the IRB had approved the protocol or a modiﬁcation. The
IRB was constituted and operated in accordance with the
principles and requirements described in the US Code of
Federal Regulations (21 CFR Part 56).
Fig. 1. Proposed metabolism of telapristone
666 Morris et al.Bioanalytical Methods
Plasma samples were analyzed for both telapristone and
CDB-4453 using LC/MS/MS. Sample analysis involved the
extraction of telapristone or CDB-4453, and the internal stand-
ard mifepristone, using protein precipitation. This extract was
then subjected to reverse-phase high-performance liquid chro-
matography on an Aquasil C18 column and detection of the
analytes by tandem mass spectroscopy using the Sciex API3000
LC/MS/MS. The lower limit of quantiﬁcation was 5 ng/mL. The
coefﬁcient of variation for intra-assay precision and accuracy
ranged from 1.5% to 4.7% and −1.0% to 5.5%, respectively.
This method was previously validated over the range of 5.00–
1,000 ng/mL with 100-μl aliquot volume.
Data Analysis
Population Pharmacokinetic Analysis
Data Handling. Due to the difference in molecular weight
of telapristone (505.6 g/mol; http://www.ama-assn.org/resources/
doc/usan/telapristone-acetate.pdf) and CDB-4453, concentrations
of telapristone and CDB-4453 were converted to equivalent
nanomolesperliter.Concentrationsof telapristone and CDB-
4453 were also log-transformed before the analysis. All
concentration values below the quantiﬁcation limit (BQL)
of the assay were excluded from the pharmacokinetic analysis.
Base Pharmacokinetic Model. Non-linear mixed-effect
model building was conducted using NONMEM® 7 (ICON
Development Solutions, Ellicott City, MD, USA) (12)w i t hG 9 5
Fortran compiler (Free Software Foundation, Boston, MA,
USA). All models were ﬁtted using the ﬁrst-order conditional
estimation method. Output was processed using PDx-Pop 4.0
(ICON Development Solutions, Ellicott City, MD, USA) and
Xpose version 4.0 (Uppsala University, Uppsala, Sweden) (13).
Graphical plots were produced using S-PLUS version 8.1
(TIBCO, Somerville, MA, USA) and R 2.11.1 (Free Software
Foundation,Boston,MA,USA).Modelselectionwasguidedby
the plausibility of the estimates, minimum objective function
value (MOFV), Akaike Information Criterion, condition num-
ber, visual inspection of diagnostic plots and the precision of
parameter estimates.
Based on visual inspection of the concentration-time
proﬁles of telapristone and CDB-4453, and previously
published data (4), two- and three-compartment pharmaco-
kinetic models for the parent and one- and two-compartment
models for the metabolite were ﬁtted to the data simulta-
neously to determine the best structural model. Elimination
was assumed to occur from the central compartment as a ﬁrst
order process, and conversion of telapristone to CDB-4453
was considered to be an irreversible process.
Interindividual variability (IIV) of the pharmacokinetic
parameters was modeled assuming a log-normal distribution,
as follows:
Pi ¼ Ppop   exp  i ðÞ
Where Pi is the estimated parameter value for individual i, Ppop
representsthetypicalpopulationestimatefortheparameterand
ηi is the deviation of Pi from Ppop.T h eη random effects were
assumedtobeindependentandsymmetricallydistributedwitha
mean of zero and variance ω
2. The magnitude of IIV was
expressed as coefﬁcient of variation (%CV).
Residual variability (RV) was modeled using a log error
model as shown below:
lnCij ¼ lnCpred;ij þ "ij
Where Cij and Cpred,ij represent the jth observed and model
predicted telapristone or CDB-4453 concentrations, respec-
tively, for individual i. εij denotes the additive residual
random error for individual i and observation j. The ε
random effects were assumed to be independent and sym-
metrically distributed with mean of zero and variance σ
2.
Covariate Analysis. Covariate analysis was performed in
order to identify additional variables that might be able to
explain the variability seen in the parameter estimates of the
base model. Continuous covariates available for screening were
age,weight,height,BMI,aspartateaminotransferase(AST)and
alanine aminotransferase (ALT), and creatinine clearance
(CrCl). Categorical covariates available were hepatic and renal
impairment status. Covariates were initially screened for
inclusion using visual inspection of the IIV versus covariates
plots and generalized additive modeling using Xpose. The
potential covariates were then tested for statistical signiﬁcance
using the stepwise forward addition, followed by stepwise
backward elimination procedure (14). An MOFV change of
3.84 (corresponding to a signiﬁcance level of 5% at 1 degree of
freedom) was used as the cutoff to include a covariate in
stepwise forward addition. For a covariate to remain in the
model during backward elimination, a change in MOFV of at
least 10.83 (corresponding to a signiﬁcance level of 0.1% at 1
degree of freedom) was needed. An improvement in the
precision of the parameter estimate (relative standard error),
and reduction in intersubject and residual variability were also
usedtodeterminetheimportanceofthecovariateasapredictor.
Mixture Model. Comparison of total clearance of telapri-
stone, via noncompartmental analysis, showed that generally,
subjects could be separated into two clearance groups based
on metabolic ratios (Fig. 2). The reason for the differences
seen in clearance is unknown. Since inclusion of covariates
did not account for the differences seen in total clearance of
telapristone, a mixture model (using the $MIXTURE sub-
routine in NONMEM©) was employed in order to model two
subpopulations for total clearance of telapristone. Because
the NONMEM© output resultso n l yg i v e st h eo v e r a l l
probability of being in a particular group, individual objective
value contributions were used to evaluate the probability of a
subject being in each population. This was done using the
method published by Carlsson et al.( 15). Where:
OFV ¼
X n
i¼1
OFVi ¼
X n
i 1
 2ln ILi ðÞ
ILi ¼
X m
k¼1
ILi;k   Ppop;k ¼
X m
k¼1
exp  OFVi;k=2 ðÞ   Ppop;k
IPk ¼
ILi;k   Ppop;k ðÞ
P m
k¼1
ILi;k   Ppop;k
the individual’s contribution to the objective function
value (OFVi) and estimated probability (P) evaluated for
667 Population Pharmacokinetics of Telapristoneall populations (pop,k ) was used to calculate that individ-
ual’s likelihood (ILi). These values were then used to
calculate the individual’s probability of belonging to either
population (IPk).
Model Evaluation. Diagnostic plots used to assess
model goodness-of-ﬁt included observed concentrations
versus population predictions (PRED), observed concen-
trations versus individual predictions (IPRED), conditional
weighted residuals (CWRES) versus PRED, and CWRES
versus time.
The standard errors of the ﬁnal model parameter
values were estimated using the non-parametric bootstrap
approach in Perl-speaks-NONMEM© (PsN©) (16). Forthe
ﬁnal model, 500 bootstrap datasets were generated. The mean
and 95% conﬁdence intervals for the population pharmacoki-
netic parameters were calculated, and compared with the
estimates from the ﬁnal model. The bootstrap 95% conﬁdence
interval was calculated based on the percentile of the empirical
distribution of the estimated parameters from the bootstrap
runs.
Model Prediction. Visual predictive check was per-
formed to evaluate the predictive ability of the ﬁnal model.
One thousand virtual observations at each sampling time
point for the full dataset (including time points for BQL data)
were simulated using the ﬁnal model parameter estimates.
The observed data were then plotted with the median and
90% prediction interval of the simulated data. Simulated
concentrations below the quantiﬁcation limit (BQL) were
excluded, and not used in the calculation of the prediction
intervals.
Secondary Parameters. Secondary parameters for each
individual were calculated using maximum a posteriori
Bayesian estimates for each individual. The equations below
were used to calculate secondary parameters:
b h 1   
¼
1
2
k24 þ k42 þ kel  
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
k24 þ k42 þ kel ðÞ
2   4   k42   kel
q   
a h 1   
¼
kel   k42
b
Where kel is the rate constant for loss from the central compartment
t1=2bðhÞ¼lnð2Þ=b
t1=2aðhÞ¼lnð2Þ=a
Simulations. Monte Carlo simulations were performed in
order to reﬂect the expected range of variability in concen-
tration values using the ﬁnal model parameter estimates.
Since telapristone is being developed for the chronic treat-
ment of endometriosis and uterine ﬁbroids, 500 simulations of
telapristone and CDB-4453 were performed at steady state,
25 mg. Total concentration (nanomoles per liter) of telapri-
stone and CDB-4453 were used in the analysis since CDB-
4453 is an active metabolite with possible equipotent anti-
progestational activity in vivo.
RESULTS
Dataset
Demographic and clinical data for subjects enrolled in
both studies are provided in Table I. There were a total of
1,805 concentration measurements for studies ZP-005 and ZP-
006. Ninety (5.0%) concentration measurements of telapristone
and CDB-4453 were BQL.
Population Pharmacokinetic Analysis
Model Development. The ﬁnal base model, shown in
Fig. 2, was a two-compartment parent, one-compartment
metabolite mixture model with ﬁrst-order absorption
without lag and ﬁrst-order elimination. The model was
parameterized in terms of absorption rate constant (Ka),
oral clearance (CL/F), apparent volume of distribution of
the central compartment (V2/F), apparent peripheral
volume of distribution for the parent (V4/F) apparent
inter-compartmentalclearance(Q/F),andapparentclearanceof
CDB-4453 (CLM/F).
Since CDB-4453 was not administered alone and the true
fraction of telapristone converted to CDB-4453 (Fmet) is
Fig. 2. Pharmacokinetic model for telapristone and CDB-4453,
where F is the oral bioavailability, Ka is the absorption rate constant,
CL/F is telapristone oral clearance, V2/F is the apparent volume of
distribution for the central compartment of telapristone, V4/F is the
apparent volume of distribution for the peripheral compartment for
telapristone, Q/F is the apparent intercompartmental clearance for
telapristone, Fmettrue is the true fraction of telapristone converted to
CDB-4453, Fmetest is the true fraction of telapristone converted to
CDB-4453 to distribution volume of CDB-4453 (Fmettrue/V3app), V3/
F is the apparent volume of distribution for CDB-4453 (V3app), and
CLM/F is the apparent clearance of CDB-4453
668 Morris et al.unknown, Fmet and V3/F are unidentiﬁable. Hence, the
apparent volume of distribution of the metabolite (V3/F) was
ﬁxed to 1 L (17). Because V3/F (Vapp) was ﬁxed to 1 L,
estimated Fmetest was then interpreted as the ratio of the
fraction of telapristone converted to CDB-4453 to the
distribution volume of CDB-4453 (Fmet/V3app).
Covariate Analysis. Renal and hepatic insufﬁciency, age,
weight, height, BMI, ALT, and AST were tested for
signiﬁcance as covariates. Moderate renal impairment was
found to be the only signiﬁcant covariate and was incorpo-
rated using a proportional covariate model.
Ka ¼  1   1 þ  2   RENAL ðÞ
Where θ1 was the estimated value for absorption rate
constant in healthy and mild renal-impaired subjects
(RENAL=0) and θ2 is the proportional constant for the
presence of moderate renal impairment (RENAL=1). Inclu-
sion of moderate renal impairment resulted in a 74%
decrease in absorption rate constant when compared to
healthy and mild renal impairment. Stochastic simulation of
concentration time proﬁles for moderate renal impaired
and healthy/mild renal impaired subjects showed that
there was on average a lower total Cmax in subjects with
moderate renal impairment (Fig. 3). In addition, evalua-
tion of post hoc estimates showed the moderate renal-
impaired subjects had a mean Ka value of 0.36±0.20 h
−1
and healthy/mild renal-impaired subjects had a mean Ka
value of 1.27±0.36 h
−1. It should be noted that there was
only limited data available on mild (n=6) and moderate
(n=6) renal-impaired subjects.
Table I. Summary of Demographic and Clinical Data for Studies ZP-005 and ZP-006
STUDY
ZP-005 ZP-006 ZP-005/006
Age, years 46 (35–61) 55 (42–66) 52.5 (35–66)
Median (range)
Weight, kg 77.3 (54.1–94.1) 70.6 (52.3–102.3) 71.65 (52.3–102.3)
Median (range)
Height, cm 163 (158–172.7) 162.6 (149–176.4) 162.6 (149–176.4)
Median (range)
BMI, kg/m
2 28 (21–36) 27 (20–34) 27 (20–36)
Median (range)
Baseline ALT, U/L 35 (17–85) 20 (7–46) 23.5 (7–85)
Median (range)
Baseline AST, U/L 40 (25–99) 21 (16–32) 24.5 (16–99)
Median (range)
Baseline CrCl, mL/min 121.2 (78.7–176.9) 73.1 (30–105) 91.45 (30–176.9)
Median (range)
Healthy (n)4 9 1 3
Moderate hepatic impairment (Child–Pugh class B) 7 – 7
Mild renal impairment (CrCl=50–80 mL/min) – 66
Moderate renal impairment (CrCl=30–50 mL/min) – 66
BMI body mass index, ALT alanine aminotransferase, AST aspartate aminotransferase, CrCl creatinine clearance
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Fig. 3. Simulated concentration time proﬁle for moderate renal impaired and healthy/mild renal impaired
subjects at 25 mg
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total clearance of telapristone resulted in a 3.15-drop in the
MOFV and IIV to decrease by 26.1% when compared to the
non-mixture model. The population estimates for apparent
oral clearance (CL/F) for the two populations were 11.6 and
3.37 L/h, respectively. Elimination half-life for the high- and
low-clearance group was 12 and 35 h, respectively. The
probability of being in the high-clearance group was 0.251,
and the low-clearance group was 0.749. Assessment of the
individual population probabilities showed that most subjects
were separated into their respective clearance groups with
very high probability.
Model Evaluation. The population pharmacokinetic
parameters along with standard errors, interindividual varia-
bility, and residual variability are presented in Table II. Basic
goodness-of-ﬁt plots for telapristone and CDB-4453 are
presented in Figs. 4 and 5. Overall, the model adequately
described the data. There appeared to be some bias in the
Table II. Pharmacokinetic Parameter Estimates, Standard Errors, and Bootstrap Results for Final Model
Parameter Estimate %RSE
Bootstrap estimate
(standard error)
Bootstrap estimate
(95% CI)
CL/F (L/h)—high clearance 11.6 36.0 12.8 (4.63) (6.50–24.28)
CL/F (L/h)—low clearance 3.34 19.1 3.31 (0.637) (2.42–4.67)
V2/F (L) 37.4 10.2 37.5 (3.83) (30.4–46)
V3/F (L) 1 –– –
V4/F (L) 120 12.4 123 (15.92) (94.6–156)
Q/F (L/h) 21.9 14.4 22.3 (3.28) (16.1–29.0)
Ka (h
−1) 1.26 7.21 1.27 (0.102) (1.10–1.51)
Moderate renal impairment on Ka −0.744 11.6 −0.722 (0.174) (−0.874–(−0.391))
Fmetest (L
−1) 0.201 16.8 0.201 (0.032) (0.137–0.267)
CLM/F (L/h) 2.43 15.1 2.41 (0.343) (1.73–3.14)
Probability 0.251 61.0 0.278 (0.131) (0.038–0.534)
IIV (variances and %CV)
IIV-CL/F 0.200 (44.7) 43.4 0.163 (0.073) (0.046–0.318)
IIV-V2/F 0.443 (66.6) 29.1 0.434 (0.142) (0.207–0.739)
IIV-V4/F 0.426 (65.3) 33.3 0.416 (0.144) (0.165–0.736)
IIV-Q/F 0.457 (67.6) 31.9 0.432 (0.145) (0.160–0.731)
IIV-Ka 0.280 (52.9) 45.7 0.263 (0.127) (0.433–0.557)
IIV-Fmetest 0.196 (44.3) 22.5 0.189 (0.044) (0.109–0.282)
RV (log error)
Telapristone (nmol/L) 0.378 15.8 0.378 (0.061) (0.267–0.516)
CDB-4453 (nmol/L) 0.109 18.6 0.109 (0.020) (0.073–0.156)
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Fig. 4. Goodness-of-ﬁt plots for telapristone (dashed lines are smoothing lines and solid lines are lines of identity)
670 Morris et al.predictions of telapristone concentrations at the earlier time
points, but evaluation of other types of absorption proﬁles
(ﬁrst order with lag, mixed, parallel, and Weibull) lead to
model instability, decrease in precision of parameter estimates,
and/or unreasonable parameter estimates.
The parameter estimates with standard error and 95%
conﬁdence interval generated from the bootstrap method are
presented in Table II. Ninety-nine percent of the runs
converged successfully. The parameter estimates obtained
from the ﬁnal model were reasonably close to the ones
obtained from the bootstrap analysis. All the parameter
estimates from the ﬁnal model were also contained within
the 95% bootstrap intervals. For the visual predictive check,
7.95% of the telapristone observations and 6.00% of CDB-
4453 observations were not contained within the 90%
prediction interval (Fig. 6).
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Fig. 5. Goodness-of-ﬁt plots for CDB-4453 (dashed lines are smoothing lines and solid lines are lines of identity)
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Fig. 6. Visual predictive check for telapristone and CDB-4453:
Observed concentration (open circles), 50th percentile (dashed line),
and 90% prediction interval (solid lines)
Table III. Steady State Pharmacokinetic Parameters (Using Total
Concentration of Telapristone and CDB-4453) for 500 Simulated
Subjects at 25 mg
25 mg Steady state
Parameter Median
5th and 95th
Percentiles
High-clearance group
Cmax (nmol/L) 1,273 538–2,750
Tmax (h) 2.00 0.750–7.00
AUCtot 0–24 (nmol*h/L) 9,141 5,507–16,288
Low-clearance group
Cmax (nmol/L) 2,308 1,099–5,266
Tmax (h) 2.00 0.25–16
AUCtot 0–24 (nmol*h/L) 22,458 11,238–46,691
671 Population Pharmacokinetics of TelapristoneSimulations. For steady-state simulation of telapristone
and CDB-4453, total Cmax, and AUC0–24 were higher in the
low-clearance group (Table III).
DISCUSSION
A two-compartment (parent) one-compartment (metabo-
lite) mixture model with ﬁrst-order absorption and elimination
adequately described the pharmacokinetics of telapristone and
CDB-4453.Thereappearedtobesomebiasinthepredictionsof
telapristone concentrations at the earlier time points such that
concentrations were underpredicted. Inspection of individual
concentration time proﬁles (observed, individual-predicted, and
population-predicted values) did not show any systematic
biases; however, there were some subjects that appeared to
exhibit a lag time while others did not.
Since Fmetest (Fmet/Vapp) was estimated to be 0.20 L
−1,
and Fmet can be no greater than 1; the apparent volume of
distribution of the metabolite (V3/F) cannot be greater than
5 L. Therefore,itappearsthatthecentralvolumeofdistribution
of the metabolite issmaller thanthat of theparent. The removal
of methyl group from a parent compound could lead to a more
polar metabolite. Therefore, the smaller volume of distribution
ofCDB-4453couldbeduetoincreasedhydrophilicityasaresult
of the removal of the methyl group.
The only signiﬁcant covariate found in this analysis was
moderate renal impairment on absorption rate constant. The effect
of renal impairment on absorption rate constant has been reported
previously in literature (18–22). Changes in the gastrointestinal
tract as a result of renal insufﬁciency could result in delayed gastric
emptying. This, in turn, can lead to a decrease in the rate of
absorption of the drug, and hence increase time to reach maximal
concentration (Tmax). Although delayed gastric emptying can lead
to an increase in Tmax, it generally does not affect the extent of
absorption (22–24). A delay in Tmax might be problematic in drugs
that are administered acutely, as the onset of a response might be
delayed. However, for chronic treatment, as is the case of
telapristone, the effect of a decrease in absorption rate constant
might be clinically irrelevant. Since creatinine clearance did not
meet the inclusion criteria to be tested as a covariate, it is believed
that the effect of moderate renal impairment is not directly
r e l a t e dt ot h ed i s e a s es t a t e( e.g., changes in glomerular ﬁltration
rate). Rather, it might be a reﬂection of other pathophysiological
states precluding or resulting from chronic renal impairment. The
lack of signiﬁcance of hepatic impairment as a covariate is
important since it is believed that the majority of telapristone is
primarily metabolized in the liver. This suggests that dosage
adjustment may not be required on a pharmacokinetic basis in
patients with mild or moderate hepatic impairment. Although the
ranges of values for the covariates tested were wide, the sample
size was very small. Therefore, a larger sample size might be
required to detect additional covariate effects.
The detection of two subpopulations for total clearance
might reﬂect the polymorphic metabolism of telapristone to
CDB-4453. The percentage of the population in the low- and
high-clearance groups was 75% and 25%, respectively. Since it is
proposed that telapristone utilizes the same metabolic pathways
as mifepristone (10,11), the cytochrome P450 (CYP) that would
be responsible for production of the major metabolites of
telapristone is CYP3A4 and 3A5. Even though there is known
pharmacokinetic interindividual variability in drugs that are
substrates for CYP3A4, there are no known polymorphisms that
result in phenotypic differences in drug metabolism (25,26). On
the other hand, CYP3A5 is known to be polymorphic and have
overlapping substrates with CYP3A4 (26–28). Studies show that
functioning CYP3A5 is present in 10–40% of the Caucasian
population, approximately 50% of African Americans, and about
33% of Asians (26,29,30). Individuals that express CYP3A5 also
express CYP3A4 and it is believed that the presence of both of
these CYPs lead to an increase in clearance of drugs that are
substrates forboth enzymes (26).Based on the percentages of the
study population in the high- and low-clearance groups, it is
hypothesized that, like mifepristone, telapristone is both a
substrate for CYP3A4 and CYP3A5. Additional studies are
needed to evaluate telapristone metabolic pathways.
Because telapristone acetate is being developed for the
chronic treatment of symptoms associated with leiomyoma
and endometriosis, steady-state simulations are important for
evaluating the pharmacokinetics of telapristone and CDB-
4453. The resulting higher total Cmax and AUC0–24 in the low-
clearance group compared to the high-clearance group at
steady state could be the result of the longer half-life of
telapristone seen in the low-clearance group. A longer half-
life could lead to greater accumulation of the drug. Therefore,
the presence of two groups for total clearance may play an
important role in the efﬁcacy/toxicity of telapristone and
CDB-4453 with long-term treatment.
CONCLUSIONS
In conclusion, a parent-metabolite mixture model
adequately described the pharmacokinetics of telapristone and
CDB-4453 after oral administration. Inclusion of a mixture
model resulted in detection of two subpopulations for the total
clearance of telapristone. Inclusion of renal impairment as a
covariate resulted in a decrease in the absorption rate constant
of telapristone. It is believed that the signiﬁcance of moderate
renal impairment on absorption rate constant was not directly
attributed to renal impairment (in terms of decrease glomerular
ﬁltration rate/changes in creatinine clearance). Rather, the
changes in absorption rate constant, was attributed to some
other disease precluding/resulting in renal impairment or other
pathophysiologic states induced by renal impairment (e.g.,
delayed gastric emptying as a result of diabetes).
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